CRISPR Therapeutics (CRSP)
CRISPR Therapeutics (NASDAQ: CRSP)
Founded: 2013
Headquarters: Zug, Switzerland
Focus Area: Development of gene-based therapeutics using CRISPR/Cas9 gene-editing technology
🔬 Key Pipelines / Technologies
| Pipeline | Indication | Clinical Stage | Notes |
|---|---|---|---|
| exa-cel | Sickle Cell Disease (SCD) and Transfusion-Dependent β-Thalassemia (TDT) | Approved | Co-developed with Vertex Pharmaceuticals |
| CTX112 | CD19+ B-cell malignancies and autoimmune diseases | Phase 1/2 | Next-generation allogeneic CAR-T therapy |
| CTX131 | CD70+ solid tumors and hematologic malignancies | Phase 1/2 | Next-generation allogeneic CAR-T therapy |
- Source: CRISPR Therapeutics Pipeline
📅 Recent Major Events
💰 Financial Information
| Item | Value |
|---|---|
| Market Capitalization | ~$3.7 billion |
| Cash Holdings | ~$1.9 billion |
| Annual R&D Spending | ~$400 million |
| Operating Loss (2024) | ~$300 million |
| Number of Employees | ~407 |
| Estimated Cash Runway | ~5 years |
Formula = (Current Assets – Current Liabilities) / Previous Year's Operating Loss
Source: CRISPR Therapeutics 2024 Annual Report
🚀 Upcoming Catalysts / Risk Factors
- Upcoming Milestones:
- Mid-2025: Broad data update for CTX112 in oncology and autoimmune indications
- 2025: Clinical data update expected for CTX131
- H1 2025: Initial clinical data readouts for new programs CTX310 and CTX320
- Risk Factors:
- Pipeline Risk: Potential failure or unexpected adverse events in clinical trials
- Regulatory Risk: Changes in global regulatory environment for gene-editing technologies
- Competitive Pressure: Intensifying competition in the gene therapy space
- Off-target Effects: Possibility of unintended gene edits inherent in CRISPR-based approaches
This content is provided for informational purposes only and does not constitute investment advice.
Investment decisions are the sole responsibility of the individual, and any gains or losses are attributable to the investor.
Updated: 2025-03-22